Nancy L Dawson1, Bryan P Hull2, Priyanka Vijapura3, Adrian G Dumitrascu3, Colleen T Ball4, Kay M Thiemann5, Michael J Maniaci3, M Caroline Burton6. 1. Division of Hospital Internal Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA. dawson.nancy11@mayo.edu. 2. Division of Hospital Internal Medicine, Mayo Clinic Hospital, Phoenix, AZ, USA. 3. Division of Hospital Internal Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA. 4. Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA. 5. Shared Services Administration, Mayo Clinic, Rochester, MN, USA. 6. Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: Home telemonitoring has been used with discharged patients in an attempt to reduce 30-day readmissions with mixed results. OBJECTIVE: To assess whether home 30-day telemonitoring after discharge for patients at high risk of readmission would reduce readmissions or mortality. DESIGN: Prospective, randomized controlled trial. PATIENTS: We compared 30-day readmission rates and mortality for patients at high risk for readmission who received home telemonitoring versus standard care between November 1, 2014, and November 30, 2018, in 2 tertiary care hospitals. INTERVENTIONS: The intervention group received home-installed equipment to measure blood pressure, heart rate, pulse oximetry, weight if heart failure was present, and glucose if diabetes was present. Results were transmitted daily and reviewed by a nurse. Both groups received standard care. MAIN MEASURES: The primary outcome was a composite end point of hospital readmission or death within 30 days after discharge. The secondary outcome was an emergency department visit within 30 days after discharge. KEY RESULTS: A total of 1380 participants (mean [SD] age, 66 [14] years; 722 [52.3%] men and 658 [47.7%] women) participated in this study. Using a modified intention-to-treat analysis, the risk of readmission or death within 30 days among patients at high readmission risk was 23.7% (137/578) in the control group and 18.2% (87/477) in the telemonitoring group (absolute risk difference, - 5.5% [95% CI, - 10.4 to - 0.6%]; relative risk, 0.77 [95% CI, 0.61 to 0.98]; P = .03). Emergency department visits occurred within 30 days after discharge in 14.2% (81/570) of patients in the control group and 8.6% (40/464) of patients in the telemonitoring group (absolute risk difference, - 5.6% [95% CI, - 9.4 to - 1.8%]; relative risk, 0.61 [95% CI, 0.42 to 0.87]; P = .005). CONCLUSIONS: Thirty days of postdischarge telemonitoring may reduce readmissions of high-risk patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02136186.
BACKGROUND: Home telemonitoring has been used with discharged patients in an attempt to reduce 30-day readmissions with mixed results. OBJECTIVE: To assess whether home 30-day telemonitoring after discharge for patients at high risk of readmission would reduce readmissions or mortality. DESIGN: Prospective, randomized controlled trial. PATIENTS: We compared 30-day readmission rates and mortality for patients at high risk for readmission who received home telemonitoring versus standard care between November 1, 2014, and November 30, 2018, in 2 tertiary care hospitals. INTERVENTIONS: The intervention group received home-installed equipment to measure blood pressure, heart rate, pulse oximetry, weight if heart failure was present, and glucose if diabetes was present. Results were transmitted daily and reviewed by a nurse. Both groups received standard care. MAIN MEASURES: The primary outcome was a composite end point of hospital readmission or death within 30 days after discharge. The secondary outcome was an emergency department visit within 30 days after discharge. KEY RESULTS: A total of 1380 participants (mean [SD] age, 66 [14] years; 722 [52.3%] men and 658 [47.7%] women) participated in this study. Using a modified intention-to-treat analysis, the risk of readmission or death within 30 days among patients at high readmission risk was 23.7% (137/578) in the control group and 18.2% (87/477) in the telemonitoring group (absolute risk difference, - 5.5% [95% CI, - 10.4 to - 0.6%]; relative risk, 0.77 [95% CI, 0.61 to 0.98]; P = .03). Emergency department visits occurred within 30 days after discharge in 14.2% (81/570) of patients in the control group and 8.6% (40/464) of patients in the telemonitoring group (absolute risk difference, - 5.6% [95% CI, - 9.4 to - 1.8%]; relative risk, 0.61 [95% CI, 0.42 to 0.87]; P = .005). CONCLUSIONS: Thirty days of postdischarge telemonitoring may reduce readmissions of high-risk patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02136186.
Authors: Patricia M Branowicki; Judith A Vessey; Dionne A Graham; Margaret A McCabe; Alison L Clapp; Kevin Blaine; Margaret R OʼNeill; Julie A Gouthro; Colleen K Snydeman; Nancy E Kline; Vincent W Chiang; Courtney Cannon; Jay G Berry Journal: J Healthc Qual Date: 2017 Nov/Dec Impact factor: 1.095
Authors: Paula de Toledo; Silvia Jiménez; Francisco del Pozo; Josep Roca; Albert Alonso; Carmen Hernandez Journal: IEEE Trans Inf Technol Biomed Date: 2006-07
Authors: Romain Kessler; Pere Casan-Clara; Dieter Koehler; Silvia Tognella; Jose Luis Viejo; Roberto W Dal Negro; Salvador Díaz-Lobato; Karina Reissig; José Miguel Rodríguez González-Moro; Gilles Devouassoux; Jean-Michel Chavaillon; Pierre Botrus; Jean-Michel Arnal; Julio Ancochea; Anne Bergeron-Lafaurie; Carlos De Abajo; Winfried J Randerath; Andreas Bastian; Christian G Cornelissen; Georg Nilius; Joëlle B Texereau; Jean Bourbeau Journal: Eur Respir J Date: 2018-01-11 Impact factor: 16.671
Authors: Michael K Ong; Patrick S Romano; Sarah Edgington; Harriet U Aronow; Andrew D Auerbach; Jeanne T Black; Teresa De Marco; Jose J Escarce; Lorraine S Evangelista; Barbara Hanna; Theodore G Ganiats; Barry H Greenberg; Sheldon Greenfield; Sherrie H Kaplan; Asher Kimchi; Honghu Liu; Dawn Lombardo; Carol M Mangione; Bahman Sadeghi; Banafsheh Sadeghi; Majid Sarrafzadeh; Kathleen Tong; Gregg C Fonarow Journal: JAMA Intern Med Date: 2016-03 Impact factor: 21.873
Authors: G Segrelles Calvo; C Gómez-Suárez; J B Soriano; E Zamora; A Gónzalez-Gamarra; M González-Béjar; A Jordán; E Tadeo; A Sebastián; G Fernández; J Ancochea Journal: Respir Med Date: 2013-12-16 Impact factor: 3.415
Authors: Joan B Soriano; Francisco García-Río; Emma Vázquez-Espinosa; Jose Ignacio Conforto; Ascensión Hernando-Sanz; Luis López-Yepes; Raúl Galera-Martínez; Germán Peces-Barba; Carolina María Gotera-Rivera; M Teresa Pérez-Warnisher; Gonzalo Segrelles-Calvo; Celia Zamarro; Pablo González-Ponce; M Inmaculata Ramos; Syed Jafri; Julio Ancochea Journal: Respir Med Date: 2018-10-13 Impact factor: 3.415
Authors: Kumar Dharmarajan; Yongfei Wang; Zhenqiu Lin; Sharon-Lise T Normand; Joseph S Ross; Leora I Horwitz; Nihar R Desai; Lisa G Suter; Elizabeth E Drye; Susannah M Bernheim; Harlan M Krumholz Journal: JAMA Date: 2017-07-18 Impact factor: 56.272
Authors: Margaret R Paulson; Karla Maita; Francisco R Avila; Ricardo A Torres-Guzman; John P Garcia; Abdullah Eldaly; Antonio J Forte; Michael J Maniaci Journal: Case Rep Surg Date: 2022-09-29